Accessibility Menu
Lakewood-Amedex Biotherapeutics logo

Lakewood-Amedex Biotherapeutics(NASDAQ) LABT

Current Price$3.37
Market Cap$5.97MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2026)-96%
5 YearN/A
1 YearN/A
1 Month-7%
Lakewood-Amedex Biotherapeutics last closing stock price
MetricPriceDate
Last closeUSD 3.412026-07-22
Lakewood-Amedex Biotherapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+40.33%USD 2.432026-07-15
1 month-6.58%USD 3.652026-06-22
3 month-96.06%USD 86.502026-04-23
Since inception-96.06%USD 86.502026-04-23

Lakewood-Amedex Biotherapeutics Financials at a Glance

Market Cap

$5.97MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$4.23

EPS (TTM)

-$8.80

P/E Ratio

-0.39

Dividend

$0.00

Beta (Volatility)

-0.33 (Low)

Price

$3.37

Volume

223,529

Open

$6.49

Previous Close

$3.41

Daily Range

$3.00 - $6.85

52-Week Range

$1.66 - $98.20

Estimated Earnings Date

N/A

LABT News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Lakewood-Amedex Biotherapeutics

Lakewood-Amedex Biotherapeutics Inc. is a biopharmaceutical company focused on developing innovative antimicrobial therapies. The company specializes in anti-infective products targeting specific viral conditions, including avian influenza and hepatitis B and C.

Products and Services
  • Innovative antimicrobial therapies for viral infections
  • Targeted treatments for avian influenza and Epstein-Barr Virus
  • Research and development of anti-infective products
Growth Outlook
  • Potential market expansion in the biopharmaceutical sector
  • Focus on developing therapies for high-demand viral conditions
  • Increased investment in research and development initiatives
Financial Highlights
  • Recent quarterly net income of -$923,291
  • Operating expenses totaled $886,750 in Q1 2026
  • Cash and cash equivalents at $11,709 as of March 31, 2026
Lakewood-Amedex Biotherapeutics Inc. operates in a niche market with significant growth potential, particularly in the development of therapies for viral infections. The company's focus on innovative solutions positions it well within the biopharmaceutical industry. Recent financial data indicates challenges, including a net loss and operating expenses, but the commitment to research and development may pave the way for future advancements and market opportunities. Investors may find interest in the company's strategic direction and potential for growth in a rapidly evolving healthcare landscape.
AI Generated • Jul 22, 2026

Industry

Biotechnology

Sector

Health Care

Employees

5

CEO

Kelvin Cooper, PhD

Website

www.lakewoodamedex.com

Headquarters

University Park, FL 34201, US

LABT Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

0.00%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

-2.56%

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

$5.97MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.75M

Volume

223.53K

Avg. Volume

1.57M

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$886.75K

EBITDA

-$886.19K

Operating Cash Flow

-$349.69K

Capital Expenditure

$0.00

Free Cash Flow

-$349.69K

Cash & ST Invst.

$11.71K

Total Debt

$1.76M

Lakewood-Amedex Biotherapeutics Performance Analysis

Lakewood-Amedex Biotherapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Lakewood-Amedex Biotherapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12026-03-31N/A
Lakewood-Amedex Biotherapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-12-31USD -12.20N/A
20242024-12-31USD -7.00-42.6%
20252025-12-31USD -8.4020.0%
Lakewood-Amedex Biotherapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12026-03-31N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$5.97MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.19M

N/A

Employees

5

N/A

Net Income

-$923.29K

N/A

EBITDA

-$886.19K

N/A

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$11.71K

N/A

Total Debt

$1.76M

N/A

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$10.30K

N/A

Short Term Debt

$1.75M

N/A

Return on Assets

N/A

N/A

Return on Invested Capital

N/A

N/A

Free Cash Flow

-$349.69K

N/A

Operating Cash Flow

-$349.69K

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,510.84+0.00%
^DJIDJI
$52,306.84+0.00%
^IXICNASDAQ
$25,750.82-0.00%
BTCBitcoin
$65,855.00-0.01%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$10.28-0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$10.96-0.02%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$40.94+0.02%
TQQQProShares Trust - ProShares UltraPro Qqq
$70.28-0.02%

Questions About LABT

What is the current price of Lakewood-Amedex Biotherapeutics?

Lakewood-Amedex Biotherapeutics is trading at $3.41 per share.

What is the 52-week range for Lakewood-Amedex Biotherapeutics?

Over the past 52 weeks, Lakewood-Amedex Biotherapeutics has traded between $1.66 and $98.20.

How much debt does Lakewood-Amedex Biotherapeutics have?

As of the most recent reporting period, Lakewood-Amedex Biotherapeutics reported total debt of $1.76M.

How much cash does Lakewood-Amedex Biotherapeutics have on hand?

Lakewood-Amedex Biotherapeutics reported $11.71K in cash and cash equivalents in its most recent financial results.

What is Lakewood-Amedex Biotherapeutics’s dividend yield?

Lakewood-Amedex Biotherapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services